On 26th August 2019, Beroni Group held the 2019 China-Japan Scientific and Technological Exchange Symposium at the China headquarters in Tianjin. The participants exchanged their ideas on Beroni Group’s research in the fields of developing new anti-cancer drugs, immunotherapy and precise diagnosis, which provided new ideas for the Group’s scientific research initiatives in China and Japan. Beroni Group plans to build an international research and development platform for cancer immunotherapy and clinical trial of new anti-cancer drugs, and to form a team of scientists consisting of researchers from China, Japan and the United States.
Prof. Takuya Tsunoda shared the current progress on the research and development of cancer immunotherapy and clinical trial technology. The research fields that Prof. Takuya Tsunoda is focusing on are closely related to Beroni’s PENAO (an anti-cancer drug) project. Beroni Group and Prof. Takuya Tsunoda discussed the joint cooperation on the development and clinical trial of this new drug. Prof. Takuya Tsunoda will form a research team in Japan to accelerate the R&D process of PENAO project.
Prof. Zhangyong Hong from School of Life Sciences of Nankai University, who focuses mainly on targeted therapy presented his research on synthetic vaccines against cancer. Mr. Jacky Zhang, Executive Chairman of Beroni Group and Prof. Hong later signed a comprehensive strategic cooperation agreement. The two sides will use their respective advantages to establish a long-term cooperative relationship, and will cooperate through various forms to achieve “school-enterprise cooperation and industry-university win-win”.
Dr. Qian Chen, CEO and Chief Scientist of Joint R&D Center of Beroni Group and ThorGene introduced gene sequencing services and the joint laboratory that will be launched at the Zhengzhou Jinshui Science & Education Park. Zhengzhou Jinshui Science & Education Park will provide local government guidance and support for the project, and Beroni Group will take advantages of its international research strength and recruit local and international talents to boost the transformation of scientific research results. Mr. Jacky Zhang, Executive Chairman of Beroni Group invited Prof. Takuya Tsunoda to participate in the project, with both sides planning to extend further cooperation.
The symposium gave a great boost to the development of Beroni Group in the field of scientific research. Beroni Group and Prof. Zhangyong Hong from School of Life Sciences of Nankai University signed a strategic cooperation agreement to jointly develop Dendritic cell-based tumor therapeutic vaccine. In addition, Beroni’s joint research team including Dr. Qian Chen, CEO and Chief Scientist of Joint R&D Center of Beroni Group and ThorGene, Dr. Zhenghu Jia, Vice President of R&D Center for Precision Medicine, Dr. Yu Wang, Researcher for Precision Medicine of Beroni Group have reached consensus with Prof. Takuya Tsunoda to jointly build an international platform for developing new drugs and cancer immunotherapy, and to set up an innovation centre and international precision medicine service centre focusing on precision diagnosis and immune cell research.
The symposium was attended by Prof. Takuya Tsunoda, Chief Scientist of R&D Team for Immunology of Beroni Group in Japan, Prof. Zhangyong Hong from School of Life Sciences of Nankai University, Dr. Qian Chen, CEO and Chief Scientist of Joint R&D Center of Beroni Group and ThorGene, Mr. Jacky Zhang, Executive Chairman of Beroni Group, Dr. Zhenghu Jia, Vice President of R&D Center for Precision Medicine, Dr. Yu Wang, Researcher for Precision Medicine of Beroni Group and senior management of Beroni Group.
